MedTrace Logo

Intravenous Exenatide in Patients With Acute Brain Injury

NCT02058940 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-07-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.

Conditions

  • Brain Injuries

Interventions

DRUG

Exenatide

50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Medtronic

    collaborator INDUSTRY

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Nicole R. Pinelli, PharmD · University of North Carolina, Chapel Hill

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058940 on ClinicalTrials.gov